Abstract
Introduction: Myo-inositol effectiveness in treating gestational diabetes remains controversial. This research was done to consolidate evidence about the efficacy and benefit of Inositol for pregnant women to reduce gestational diabetes risk.
Methods: This study was done in compliance with the 2020 PRISMA guidelines and Cochrane Handbooks for Systematic Reviews of Interventions .Up to January 2022, PubMed, Scopus, Web of Science, and the Cochrane library were searched to identify randomized controlled trials (RCTs) examining the efficacy of Inositol on gestational diabetes mellitus in pregnant women, and we combined all relevant outcomes in a meta-analysis using Review Manager Software.
Results: Seven RCTs were initially included. However, the meta-analysis included only six. The pooled risk ratio indicated that myo-inositol supplementation significantly reduce gestational diabetes risk [RR=0.67, 95% CI (0.40, 1.12)], gestational hypertension [RR=0.49, 95% CI, (0.29, 0.82), P=0.006], and preterm delivery [RR=0.48, 05% CI, (0.31, 0.75), P=0.001]. However, no significant difference was observed in gestational age at delivery (days), cesarean delivery percentage, incidence of macrosomia, NICU admission, shoulder dystocia, neonatal hypoglycemia, and birth weight.
Conclusion: Supplemental myo-inositol for pregnant woman may lower the likelihood of developing of gestational diabetes, gestational hypertension, and premature birth.